{ "schemaVersion": 2, "eyebrow": "Gastroenterology", "title": "Extraintestinal Manifestations of Inflammatory Bowel Disease", "summary": "A practical approach to recognizing inflammatory bowel disease–associated musculoskeletal, skin, ocular, hepatobiliary, renal, and systemic disease; separating activity-linked manifestations from independent disease; and coordinating bowel-directed and organ-specific management.", "seoDescription": "Clinical approach to extraintestinal manifestations of IBD, including arthritis, skin and eye disease, primary sclerosing cholangitis, and renal complications.", "clinicalQuestion": "How should physicians identify, triage, and manage extraintestinal manifestations in patients with inflammatory bowel disease?", "specialty": "Gastroenterology", "audience": "U.S. physicians and medical trainees", "tags": [ "inflammatory bowel disease", "extraintestinal manifestations", "Crohn disease", "ulcerative colitis", "IBD arthritis", "uveitis", "pyoderma gangrenosum", "primary sclerosing cholangitis" ], "keyTakeaways": [ "Ask specifically about joint, skin, eye, renal, and hepatobiliary symptoms at diagnosis and during follow-up; up to 47% of patients with IBD develop at least one extraintestinal manifestation. [1]", "Erythema nodosum and episcleritis often parallel ulcerative colitis activity, whereas pyoderma gangrenosum, uveitis, and primary sclerosing cholangitis can progress independently of intestinal inflammation. [1]", "A painful red eye with visual symptoms requires urgent ophthalmologic assessment because uveitis is an IBD-associated manifestation and should not be managed as uncomplicated episcleritis. [1][3]", "Do not attribute every systemic complaint to active IBD: anemia and hypoalbuminemia may produce dyspnea or peripheral edema, while nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis, and amyloidosis are recognized renal manifestations. [1]", "For suspected Crohn disease, establish the intestinal diagnosis by integrating compatible symptoms with endoscopic findings, histology, and imaging; complications and extraintestinal disease then influence phenotype and treatment selection. [14]" ], "sections": [ { "id": "triage-and-first-assessment", "eyebrow": "Initial assessment", "heading": "Triage organ-threatening manifestations before attributing symptoms to an IBD flare", "intro": "Prioritize eye, hepatobiliary, renal, and destructive skin or joint presentations.", "paragraphs": [ "At every IBD evaluation, document new inflammatory joint symptoms, eye pain or redness, oral lesions, tender nodules or ulceration, urinary symptoms or renal dysfunction, and cholestatic symptoms. IBD-associated extraintestinal manifestations involve joints, skin, eyes, kidneys, and the hepatobiliary system; more than one manifestation may coexist. [1]", "Escalate immediately for a painful red eye, photophobia, reduced vision, or suspected uveitis; ocular inflammation is included among recognized IBD complications, and uveitis may progress independently of bowel activity. [1][3] A red eye that is limited to episcleritis is more likely to track colitis activity, but the distinction should not delay ophthalmologic assessment when visual symptoms or significant pain are present. [1]", "Treat rapidly progressive painful cutaneous ulceration as possible pyoderma gangrenosum rather than assuming cellulitis or a routine IBD flare. Pyoderma gangrenosum may occur and progress independently of bowel inflammation; coordinate dermatology evaluation while reassessing intestinal inflammatory control. [1]", "For new dyspnea, edema, weight loss, fever, abdominal mass, fistula drainage, or perianal pain, determine whether the driver is intestinal inflammation, IBD complication, or systemic consequence. Anemia and hypoalbuminemia can cause dyspnea and peripheral edema, while Crohn disease can be complicated by obstruction, abscess, sinus tracts, and fistulas. [1][14]" ], "bullets": [ "Urgent same-day pathway: painful or photophobic red eye, vision change, or suspected uveitis. [1][3]", "Prompt multidisciplinary pathway: ulcerative skin disease suggestive of pyoderma gangrenosum, active fistula or perianal abscess, or suspected hepatobiliary or renal involvement. [1][14]", "Reassess intestinal activity concurrently, but do not use a quiet bowel history to exclude uveitis, pyoderma gangrenosum, or primary sclerosing cholangitis. [1]" ], "subsections": [], "table": { "caption": "IBD-associated manifestations differ in their relationship to intestinal inflammatory activity. [1]", "columns": [ "Clinical pattern", "Relationship to bowel activity", "Immediate decision" ], "rows": [ [ "Erythema nodosum", "Often occurs concurrently with ulcerative colitis flares. [1]", "Assess and treat intestinal inflammatory activity while documenting skin severity. [1]" ], [ "Episcleritis", "Often occurs concurrently with ulcerative colitis flares. [1]", "Evaluate for eye pain or visual symptoms that would instead raise concern for uveitis. [1]" ], [ "Pyoderma gangrenosum", "May occur and progress independently of bowel inflammation. [1]", "Obtain dermatologic assessment and optimize IBD management without assuming bowel remission will resolve the lesion. [1]" ], [ "Uveitis", "May occur and progress independently of bowel inflammation. [1]", "Urgently involve ophthalmology when symptomatic ocular inflammation is suspected. [1][3]" ], [ "Primary sclerosing cholangitis", "May occur and progress independently of bowel inflammation. [1]", "Evaluate hepatobiliary disease separately from intestinal activity. [1]" ] ] } }, { "id": "confirm-ibd-activity-and-exclude-mimics", "eyebrow": "Diagnostic branch point", "heading": "Establish whether intestinal inflammation is active before linking a manifestation to IBD", "intro": "Correlate organ findings with objective bowel assessment rather than symptoms alone.", "paragraphs": [ "When an extraintestinal manifestation is new or worsening, first determine whether there is concurrent intestinal activity or an alternative trigger. In ulcerative colitis, diagnosis requires endoscopy with biopsy and negative stool culture; obtain stool culture in every flare because relapse may be associated with pathogens. [15][16] This prevents escalation of immunosuppression for infectious diarrhea mislabeled as active colitis.", "For suspected or newly characterized Crohn disease, integrate compatible clinical features with endoscopy, histology, and cross-sectional or other appropriate imaging. Crohn disease may involve any GI segment and is transmural, creating a separate pathway for strictures, perforation, abscesses, sinuses, fistulas, and perianal disease. [2][14]", "Use objective clinical findings to define accompanying disease burden. In the Crohn Disease Activity Index, listed complications include arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, anal fistula or abscess, other fistula, and fever above 37.8°C; these findings should be recorded rather than collapsed into a nonspecific report of 'systemic symptoms.' [3]", "In pediatric Crohn disease, fever at least 38.5°C for 3 days in the preceding week, definite arthritis, uveitis, erythema nodosum, or pyoderma gangrenosum count as extraintestinal manifestations in the Pediatric Crohn Disease Activity Index. Low albumin, elevated erythrocyte sedimentation rate, weight loss, and perianal findings add objective evidence of systemic and intestinal burden. [13]" ], "bullets": [ "Ulcerative colitis flare: obtain stool culture before assigning new skin, joint, or eye symptoms solely to colitis activity. [15][16]", "Crohn disease phenotype: identify penetrating, stricturing, and perianal disease because these complications require management beyond treatment of luminal symptoms. [2][14]", "Document anemia and albumin status when dyspnea or edema accompanies suspected inflammatory activity. [1]" ], "subsections": [], "table": { "caption": "Objective findings that change attribution of symptoms in IBD. [1][3][13][15][16]", "columns": [ "Finding", "Interpretation", "Next action" ], "rows": [ [ "Positive stool culture during apparent ulcerative colitis relapse", "An enteric pathogen may account for or contribute to flare-like symptoms. [15][16]", "Address infection before attributing symptoms exclusively to active ulcerative colitis. [15][16]" ], [ "Endoscopy with biopsy plus negative stool culture", "Supports ulcerative colitis diagnosis in the appropriate clinical setting. [15][16]", "Use extent and severity to guide colitis-directed therapy. [15][16]" ], [ "Crohn-compatible imaging, endoscopy, histology, and symptoms", "Confirms Crohn disease through multimodal correlation. [14]", "Assess for transmural complications and perianal disease. [2][14]" ], [ "Anemia or hypoalbuminemia with dyspnea or edema", "May explain systemic symptoms without identifying a new organ-specific extraintestinal manifestation. [1]", "Evaluate and correct the underlying intestinal and nutritional/inflammatory drivers. [1]" ] ] } }, { "id": "musculoskeletal-and-mucocutaneous-patterns", "eyebrow": "Common clinical patterns", "heading": "Separate inflammatory musculoskeletal and mucocutaneous disease from bowel activity-linked findings", "intro": "The activity relationship determines whether bowel control alone is likely to be sufficient.", "paragraphs": [ "Arthritis is among the most commonly recognized extraintestinal manifestations of IBD, and peripheral arthritis, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, psoriasis, and uveitis are described in pediatric IBD. [1][2] For every patient with joint complaints, record the distribution, functional limitation, objective swelling, and coexistence of skin, eye, oral, or bowel activity because these features determine whether the presentation fits an inflammatory multisystem pattern.", "When erythema nodosum or episcleritis appears during worsening ulcerative colitis symptoms, prioritize confirmation and control of colitis activity because these manifestations often occur concurrently with flares. [1] Conversely, persistent arthritis, pyoderma gangrenosum, or uveitis despite apparently controlled bowel symptoms should trigger organ-specific assessment rather than repeated empiric escalation based only on gastrointestinal symptoms. [1]", "Aphthous stomatitis, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, arthritis or arthralgia, and fever are explicit complication variables in the Crohn Disease Activity Index. [3] Their presence should be captured longitudinally, because a change in these variables may represent clinically meaningful disease burden even when stool frequency alone is unchanged.", "In children with Crohn disease and coexistent inflammatory arthritis, methotrexate is identified as particularly suitable as a first-line maintenance option; the cited pediatric regimen is 15 mg/m² subcutaneously once weekly, maximum 25 mg, with folate supplementation. [13] This is pediatric Crohn disease guidance and should not be extrapolated as a universal adult regimen or as acute therapy for any individual extraintestinal manifestation." ], "bullets": [ "Activity-linked pattern: erythema nodosum or episcleritis emerging with ulcerative colitis flare symptoms. [1]", "Activity-independent pattern: pyoderma gangrenosum, uveitis, or primary sclerosing cholangitis despite quiescent intestinal symptoms. [1]", "Pediatric Crohn disease with coexistent inflammatory arthritis: consider methotrexate maintenance selection in the context of the full Crohn treatment plan. [13]" ], "subsections": [], "table": { "caption": "Musculoskeletal and mucocutaneous manifestations that should be explicitly documented in IBD assessment. [2][3][13]", "columns": [ "Manifestation", "Where it informs assessment", "Practical implication" ], "rows": [ [ "Arthritis or arthralgia", "Included among Crohn Disease Activity Index complications; inflammatory arthritis is also recognized in pediatric IBD. [2][3]", "Assess for concurrent bowel, skin, ocular, and perianal disease. [2][3]" ], [ "Aphthous stomatitis", "Included among Crohn Disease Activity Index complications and pediatric IBD extraintestinal manifestations. [2][3]", "Document as inflammatory disease burden and evaluate accompanying manifestations. [2][3]" ], [ "Erythema nodosum", "Included in Crohn activity assessment and may parallel ulcerative colitis flares. [1][3]", "Reassess intestinal activity. [1]" ], [ "Pyoderma gangrenosum", "Included in Crohn activity assessment but may progress independently of bowel inflammation. [1][3]", "Obtain organ-specific evaluation while managing IBD activity. [1]" ] ] } }, { "id": "ocular-hepatobiliary-and-renal-disease", "eyebrow": "High-consequence branches", "heading": "Evaluate eye, liver-biliary, and kidney disease as parallel IBD complications", "intro": "These manifestations can require independent surveillance and treatment pathways.", "paragraphs": [ "Do not infer ocular severity from bowel activity. Episcleritis may occur with ulcerative colitis flares, whereas uveitis may occur and progress independently of bowel inflammation. [1] The decision point is symptom severity: pain, photophobia, or visual change warrants urgent ophthalmologic evaluation rather than observation for response to gastrointestinal treatment.", "Primary sclerosing cholangitis is a recognized hepatobiliary manifestation of IBD and may progress independently of intestinal inflammation. [1] New cholestatic laboratory abnormalities or hepatobiliary symptoms should therefore prompt a liver-focused assessment rather than be interpreted as evidence of inadequate control of colitis alone.", "Renal manifestations of IBD include nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis. [1] In a patient with flank pain, hematuria, proteinuria, rising creatinine, or edema, separate stone disease from intrinsic renal disease and from edema attributable to hypoalbuminemia; renal findings should not be dismissed as nonspecific extraintestinal symptoms. [1]", "IBD with primary sclerosing cholangitis carries important colorectal cancer implications. In a national cohort, IBD overall was associated with increased colorectal cancer risk versus controls (hazard ratio 1.83, 95% CI 1.72-1.96), and risk was highest initially among patients with PSC before decreasing over time. [24] Use PSC status as a major risk modifier when planning longitudinal colorectal neoplasia surveillance." ], "bullets": [ "Eye: distinguish painless superficial redness from painful, photophobic, or vision-threatening inflammation; urgent ophthalmology is indicated for the latter pattern. [1][3]", "Hepatobiliary: evaluate suspected PSC independently because its course need not mirror intestinal inflammatory activity. [1]", "Kidney: evaluate nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis as distinct diagnostic possibilities. [1]", "Cancer risk: recognize PSC as an important modifier of colorectal cancer risk in IBD surveillance planning. [24]" ], "subsections": [], "table": { "caption": "High-consequence organ involvement in IBD. [1][24]", "columns": [ "Organ system", "Recognized IBD-associated disease", "Decision consequence" ], "rows": [ [ "Eye", "Episcleritis and uveitis. [1]", "Uveitis may be independent of bowel activity; urgent ophthalmologic assessment is appropriate when symptoms suggest intraocular inflammation. [1][3]" ], [ "Hepatobiliary", "Primary sclerosing cholangitis. [1]", "Evaluate and monitor as a parallel disease process; do not use bowel remission to exclude progression. [1]" ], [ "Kidney", "Nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis. [1]", "Use renal findings to direct a renal-specific differential rather than attributing all symptoms to colitis. [1]" ], [ "Colon", "Colorectal cancer risk is increased in IBD; PSC identifies a particularly high-risk subgroup. [24]", "Incorporate PSC status into colorectal cancer surveillance planning. [24]" ] ] } }, { "id": "treatment-coordination-and-monitoring", "eyebrow": "Management framework", "heading": "Coordinate bowel-directed therapy with organ-specific management and longitudinal documentation", "intro": "The treatment target is not only stool control but control of clinically consequential inflammatory burden.", "paragraphs": [ "When a manifestation tracks intestinal activity, treat the active bowel disease after objective reassessment and exclusion of infectious relapse, particularly in ulcerative colitis where stool culture should be obtained in every flare. [15][16] Erythema nodosum and episcleritis are examples of manifestations that commonly coincide with ulcerative colitis flares. [1]", "When a manifestation is independent of bowel activity, avoid a bowel-only management plan. Uveitis, pyoderma gangrenosum, and primary sclerosing cholangitis may progress despite improvement in luminal inflammation, requiring concurrent ophthalmologic, dermatologic, or hepatobiliary management. [1] In Crohn disease, treatment planning also must account for stricturing, penetrating, and perianal complications, which may require interventions beyond medical treatment of luminal disease. [2][14]", "Use standardized documentation to monitor both intestinal and extraintestinal response. Crohn Disease Activity Index complication fields capture arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, fistulas or abscesses, and fever above 37.8°C. [3] In pediatric assessment, document fever at least 38.5°C for 3 days, definite arthritis, uveitis, erythema nodosum, and pyoderma gangrenosum, alongside albumin, erythrocyte sedimentation rate, growth, weight, and perianal findings. [13]", "Refer early for coordinated specialty care when IBD is diagnosed or when advanced therapies and serious adverse-effect monitoring are required. Crohn disease management requires specialist input from diagnosis because regimens require frequent response assessment and expertise in managing potentially serious adverse events. [14] This need is amplified when an extraintestinal manifestation is organ-threatening, refractory, or discordant with intestinal activity." ], "bullets": [ "At follow-up, record whether each manifestation improved, worsened, or remained unchanged relative to intestinal symptoms and objective bowel findings. [1][3]", "For ulcerative colitis flare symptoms, obtain stool culture before treatment escalation. [15][16]", "For Crohn disease, separately identify abscess, obstruction, fistula, sinus tract, and perianal disease because they alter management beyond luminal symptom control. [14]" ], "subsections": [], "table": { "caption": "Follow-up framework for IBD extraintestinal manifestations. [1][3][13][14][15][16]", "columns": [ "Follow-up domain", "What to document", "Action if discordant with bowel activity" ], "rows": [ [ "Intestinal disease", "Symptoms, endoscopic and histologic context when reassessment is needed, and stool culture during ulcerative colitis relapse. [14][15][16]", "Exclude infection and reassess disease phenotype before escalating therapy. [14][15][16]" ], [ "Eyes", "Episcleritis versus symptoms concerning for uveitis; pain, photophobia, and visual symptoms. [1][3]", "Urgently involve ophthalmology for suspected uveitis. [1][3]" ], [ "Skin and joints", "Arthritis or arthralgia, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, and functional impact. [2][3]", "Pursue organ-specific assessment when manifestations persist despite intestinal improvement. [1]" ], [ "Hepatobiliary and renal disease", "PSC status, renal symptoms, kidney function abnormalities, hematuria, proteinuria, and edema. [1][24]", "Evaluate PSC and renal disease through dedicated diagnostic pathways; incorporate PSC into colorectal cancer risk planning. [1][24]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "CENTER FOR DRUG EVALUATION AND RESEARCH", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "Pediatric Inflammatory Bowel Disease: Developing Drugs ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/180126/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 3, "title": "Crohn's Disease: Developing Drugs for Treatment", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/158001/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 4, "title": "Comorbidities in inflammatory bowel disease: a call for action", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30173-6/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 5, "title": "Inflammatory bowel diseases", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/collections/inflammatory-bowel-diseases?startPage=1&pageSize=100", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 6, "title": "Endpoints for extraintestinal manifestations in inflammatory ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00297-1/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 7, "title": "Arthritis complicating inflammatory bowel disease", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00132-2/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 8, "title": "Extraintestinal Manifestations of Idiopathic Inflammatory ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/609396", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 9, "title": "and Inflammatory Bowel Disease", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamasurgery/articlepdf/595982/archsurg_129_7_019.pdf?resultClick=1", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 10, "title": "Inflammatory Bowel Disease in Children and Adolescents", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/PEDS/articlepdf/2446194/prv150010supp1_prod.pdf", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 11, "title": "Defining Mucocutaneous Crohn Disease", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamadermatology/articlepdf/2833463/jamadermatology_ramseier_2025_ed_250004_1748911541.06934.pdf?resultClick=1", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 12, "title": "Combining advanced therapies in patients with ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/early/2025/11/17/flgastro-2024-102967", "authors": "fg.bmj.com", "host": "fg.bmj.com" }, { "number": 13, "title": "Management of Crohn's disease", "detail": "adc.bmj.com", "url": "https://adc.bmj.com/content/archdischild/early/2015/11/08/archdischild-2014-307217.full.pdf", "authors": "adc.bmj.com", "host": "adc.bmj.com" }, { "number": 14, "title": "Crohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/42", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 15, "title": "Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/43", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 16, "title": "Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/43", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 17, "title": "Rise of precision medicine: can it deliver on its promise in IBD? | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/75/1/176", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 18, "title": "Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives", "detail": "spj.science.org", "url": "https://spj.science.org/doi/10.1016/j.csbj.2025.02.026", "authors": "spj.science.org", "host": "spj.science.org" }, { "number": 19, "title": "Beyond the Gut: A Systematic Review and Meta-analysis of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ecco-jcc/article/18/6/851/7512824", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 20, "title": "First European Evidence-based Consensus on Extra-intestinal ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ecco-jcc/article/10/3/239/2462512", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 21, "title": "Safety and Effectiveness of Combining Biologics and Small ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/crohnscolitis360/article/4/1/otac002/6526413", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 22, "title": "S955 Effectiveness of Vedolizumab in Patients... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0000860460.33213.97~s955effectiveness-of-vedolizumab-in-patients-with", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 23, "title": "Gastroenterology | DDW® 2026 Abstracts", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/journal/gastroenterology/vol/170/issue/6/suppl/S?page=23", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 24, "title": "Impact of Inflammatory Bowel Disease and Primary... : Clinical Gastroenterology & Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/01817247-202602000-00025", "authors": "journals.lww.com", "host": "journals.lww.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "CENTER FOR DRUG EVALUATION AND RESEARCH", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "many extraintestinal manifestations (EIMs), which have been reported to affect a wide variety of organ systems, most commonly joints, skin, eyes, kidneys, and hepatobiliary tract.7 Renal manifestations of IBD may include nephrolithiasis, amyloidoisis, tubulointerstitial nephritis, and glomerulonephr", "score": 0.71425 }, { "number": 2, "title": "Pediatric Inflammatory Bowel Disease: Developing Drugs ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/180126/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "characterized by transmural inflammation that may affect any segment(s) 47 of the gastrointestinal tract from the mouth to the anus and may be associated with fibrosis, 48 strictures, and perforations. Clinical signs and symptoms of pediatric CD include abdominal 49 pain, diarrhea, fatigue, weight l", "score": 0.48279548 }, { "number": 3, "title": "Crohn's Disease: Developing Drugs for Treatment", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/158001/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Service Act (42 U.S.C. 262) and 21 CFR parts 312, 314, and 601for treating 20 CD. Specifically, this guidance addresses FDA’s current thinking about the necessary attributes 21 of clinical trials for drugs being developed for treating CD, including trial population, trial 22 design, efficacy conside", "score": 0.41634628 }, { "number": 4, "title": "Comorbidities in inflammatory bowel disease: a call for action", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30173-6/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by M Argollo · 2019 · Cited by 262 — Inflammatory bowel disease (IBD) is a chronic systemic inflammatory condition. extraintestinal manifestations of IBD, including arthritis, psoriasis, and", "score": 0.64047897 }, { "number": 5, "title": "Inflammatory bowel diseases", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/collections/inflammatory-bowel-diseases?startPage=1&pageSize=100", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "Review. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the", "score": 0.60274047 }, { "number": 6, "title": "Endpoints for extraintestinal manifestations in inflammatory ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00297-1/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by L Guillo · 2022 · Cited by 43 — Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic", "score": 0.5832277 }, { "number": 7, "title": "Arthritis complicating inflammatory bowel disease", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00132-2/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by K Song · 2024 · Cited by 14 — Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis Therap Adv", "score": 0.5221784 }, { "number": 8, "title": "Extraintestinal Manifestations of Idiopathic Inflammatory ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/609396", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "by JT Danzi · 1988 · Cited by 213 — Some of these extraintestinal manifestations are related to active colitis—joint, skin, ocular, and oral; small bowel dysfunction—cholelithiasis and", "score": 0.5068117 }, { "number": 9, "title": "and Inflammatory Bowel Disease", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamasurgery/articlepdf/595982/archsurg_129_7_019.pdf?resultClick=1", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Clinical course and evolution of ery- thema nodusum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985", "score": 0.50490767 }, { "number": 10, "title": "Inflammatory Bowel Disease in Children and Adolescents", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/PEDS/articlepdf/2446194/prv150010supp1_prod.pdf", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Extraintestinal Manifestations of Inflammatory Bowel. Disease in Children and Adolescents. Dermatologic. Erythema nodosum. Pyoderma gangrenosum. Musculoskeletal.", "score": 0.49626526 }, { "number": 11, "title": "Defining Mucocutaneous Crohn Disease", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/jamadermatology/articlepdf/2833463/jamadermatology_ramseier_2025_ed_250004_1748911541.06934.pdf?resultClick=1", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Colitis Organization considered oral CD an extraintestinal mani- festation of inflammatory bowel disease (IBD).11. Since CD is defined as inflammation of any", "score": 0.48982134 }, { "number": 12, "title": "Combining advanced therapies in patients with ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/early/2025/11/17/flgastro-2024-102967", "authors": "fg.bmj.com", "host": "fg.bmj.com", "snippet": "by B Gros · 2025 · Cited by 2 — Inflammatory bowel disease (IBD) frequently coexists with extraintestinal manifestations/immune-mediated inflammatory diseases (IMIDs), adding", "score": 0.6139086 }, { "number": 13, "title": "Management of Crohn's disease", "detail": "adc.bmj.com", "url": "https://adc.bmj.com/content/archdischild/early/2015/11/08/archdischild-2014-307217.full.pdf", "authors": "adc.bmj.com", "host": "adc.bmj.com", "snippet": "Stools (per day) 0=0–1 liquid stools, no blood 7.5=up to 2 semiformed with small blood, or 2–5 liquid 15=gross bleeding, or ≥6 liquid or nocturnal diarrhoea ______ Laboratory Erythrocyte sedimentation rate 0≤20 mm/h 7.5=20–50 mm/h 15≥50 mm/h ______ Albumin 0≥3.5 g/dL 10=3.1–3.4 g/dL 20≤3.0 g/dL ____", "score": 0.5553635 }, { "number": 14, "title": "Crohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/42", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Diagnosis is confirmed by correlating imaging, endoscopic findings, and histology, with clinical symptoms consistent with inflammatory bowel disease.\n\nSpecialist input is required from the time of diagnosis, as treatment regimens require frequent monitoring of clinical response, knowledge of common ", "score": 0.51413256 }, { "number": 15, "title": "Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/43", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal pain, faecal urgency, and extraintestinal manifestations, particularly those related to activity of the colitis.\n\nDiagnosis requires endoscopy with biopsy and negative stool culture.\n\nRelapses are often assoc", "score": 0.47154015 }, { "number": 16, "title": "Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/43", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Patients commonly experience bloody diarrhea, chronic diarrhea (or both), lower abdominal pain, fecal urgency, and extraintestinal manifestations, particularly those related to activity of the colitis.\n\nDiagnosis requires endoscopy with biopsy and negative stool culture.\n\nRelapses are often associat", "score": 0.4611872 }, { "number": 17, "title": "Rise of precision medicine: can it deliver on its promise in IBD? | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/75/1/176", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "and stool will be essential to inform routine clinical surveillance strategies of CDC (figure 4 Hallmarks of MRD). This concept is inherently dynamic—much like the hallmarks of cancer119 120—and will continue to evolve with the emergence of new biomarkers and patient-centred assessments. Importantly", "score": 0.4465194 }, { "number": 18, "title": "Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives", "detail": "spj.science.org", "url": "https://spj.science.org/doi/10.1016/j.csbj.2025.02.026", "authors": "spj.science.org", "host": "spj.science.org", "snippet": "UC is a chronic inflammatory disease affecting mainly the mucous membrane of the colon and rectum. As a result of the disease, the integrity of the mucous membrane is damaged: firstly, the mucus is disrupted, its function, layer thickness and microbial content changes ( Symptoms include bloody diarr", "score": 0.52451706 }, { "number": 19, "title": "Beyond the Gut: A Systematic Review and Meta-analysis of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ecco-jcc/article/18/6/851/7512824", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by ÁE Tímár · 2024 · Cited by 22 — Extraintestinal manifestations are frequent in patients with inflammatory bowel disease and have a negative impact on quality.", "score": 0.60498303 }, { "number": 20, "title": "First European Evidence-based Consensus on Extra-intestinal ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ecco-jcc/article/10/3/239/2462512", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by M Harbord · 2016 · Cited by 1087 — Up to 50% of patients with inflammatory bowel disease [IBD] experience at least one extra-intestinal manifestation [EIM], which can present before IBD is ...Read more", "score": 0.53968745 }, { "number": 21, "title": "Safety and Effectiveness of Combining Biologics and Small ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/crohnscolitis360/article/4/1/otac002/6526413", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by QA Alayo · 2022 · Cited by 100 — Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic", "score": 0.42448413 }, { "number": 22, "title": "S955 Effectiveness of Vedolizumab in Patients... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0000860460.33213.97~s955effectiveness-of-vedolizumab-in-patients-with", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Journals\n\nCrossmark: Check for updates\n\n# S955 Effectiveness of Vedolizumab in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis\n\n## Article Level Metrics\n\n## Related Articles\n\n## Readers Of this Article Also Read\n\n## Most Popular Articles\n\nwk-lippincott-logo\npr", "score": 0.39550823 }, { "number": 23, "title": "Gastroenterology | DDW® 2026 Abstracts", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/journal/gastroenterology/vol/170/issue/6/suppl/S?page=23", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "... INFLAMMATORY BOWEL DISEASE COHORT: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM ... BOWEL DISEASE DIAGNOSIS: A NATIONWIDE COHORT STUDY", "score": 0.3839421 }, { "number": 24, "title": "Impact of Inflammatory Bowel Disease and Primary... : Clinical Gastroenterology & Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/01817247-202602000-00025", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Crossmark: Check for updates\n\n# Impact of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis on Colorectal Cancer Risk: National Cohort Study\n\norcid icon\n\n## Background & Aims\n\nInflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC). Previous studies concluded that ", "score": 0.37800032 } ], "publishedAt": "2026-08-24T16:38:05.158890+00:00", "updatedAt": "2026-08-24T16:38:05.158890+00:00", "readingMinutes": 7, "slug": "extraintestinal-manifestations-of-inflammatory-bowel-disease" }